Free Submission Public Relations &
Deutsch English


Free Research Reports on ANAC, GE, OMPI and PCYC Issued by the Paragon Report Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

Print article Print article
© Marketwire 2013
2013-04-09 14:26:56 -

NEW YORK, NY -- (Marketwired) -- 04/09/13 -- The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Anacor Pharmaceuticals Inc. (NASDAQ: ANAC) shares spiked 14.0 percent on volume of 2.19 million shares traded Monday to close at $6.84 a share. The company announced that the Bill & Melinda Gates Foundation has agreed to provide funding to help supports its development of drugs for tuberculosis and two filarial worm diseases.

Find out more about Anacor Pharmaceuticals including full access to the free equity report at: :

General Electric Company (NYSE: GE) shares have gained approximate 10 percent year-to-date. The company has recently agreed to purchase a global supplier of artificial lift products, Lufkin, for roughly $3.3 billion in cash, or $88.50 a share.

Find out more about General Electric including full access to the free equity report at: :

Obagi Medical Products, Inc. (NASDAQ: OMPI) shares declined 5.66 percent on volume of nearly 3 million shares traded Monday to close at $23.98 a share. Merz Pharma Group has recently withdrawn its offer to purchase Obagi Medical for approximately $385 million.

Find out more about Obagi Medical Products including full access to the free equity report at: :

Pharmacyclics, Inc. (NASDAQ: PCYC) shares spiked sharply in early trading Monday before closing at $76.76 a share, an increase of 1.6 percent. The company announced that the FDA has granted an additional Breakthrough Therapy Designation for ibrutinib monotherapy for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

Find out more about Pharmacyclics including full access to the free equity report at: :

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact :

Press Information:

Contact Person:

Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact